

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>EDB Investments Pte Ltd.</u> (Last) (First) (Middle) 20 BIOPOLIS WAY #09-01 (Street) CENTROS U0 138668 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 02/09/2011	3. Issuer Name and Ticker or Trading Symbol <u>FLUIDIGM CORP [FLDM]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series E Preferred Warrant (Right to Buy)	(1)	(2)	Common Stock	43,853 ⁽¹⁾⁽⁵⁾	24.22	D ⁽³⁾⁽⁴⁾	
Series E Preferred Stock	(1)	(6)	Common Stock	1,047,955 ⁽¹⁾⁽⁵⁾	0	D ⁽³⁾⁽⁴⁾	
Series D Preferred Stock	(7)	(7)	Common Stock	623,531 ⁽⁵⁾⁽⁷⁾	0	D ⁽³⁾⁽⁴⁾	
Series C Preferred Stock	(7)	(7)	Common Stock	128,025 ⁽⁵⁾⁽⁷⁾	0	D ⁽⁴⁾⁽⁸⁾	

1. Name and Address of Reporting Person* <u>EDB Investments Pte Ltd.</u> (Last) (First) (Middle) 20 BIOPOLIS WAY #09-01 (Street) CENTROS U0 138668 (City) (State) (Zip)		
---	--	--

1. Name and Address of Reporting Person* <u>Biomedical Sciences Investment Fund Pte Ltd.</u> (Last) (First) (Middle) 20 BIOPOLIS WAY #09-01 (Street) CENTROS U0 138668 (City) (State) (Zip)		
---	--	--

1. Name and Address of Reporting Person* <u>SINGAPORE BIO INNOVATIONS PTE LTD</u> (Last) (First) (Middle) 250, NORTH BRIDGE ROAD #20-02 RAFFLES CITY TOWER (Street) SINGAPORE U0 179101		
---	--	--

(City) (State) (Zip)

Explanation of Responses:

1. Reflects the automatic conversion of each share of Series E Preferred Stock into 1.3 shares of Common Stock to occur upon the closing of the Issuer's initial public offering.
2. Expires immediately prior to the closing of the Issuer's initial public offering.
3. Biomedical Sciences Investment Fund Pte Ltd is the record holder of the securities reported on Lines 1, 2 and 3 of Table 2.
4. EDB Investments Pte Ltd, or EDB Investments, is the parent entity of Biomedical Sciences Investment Fund Pte Ltd and Singapore Bio-Innovations Pte Ltd. The Economic Development Board of Singapore, or EDB, is the parent entity of EDB Investments. EDB is a Singapore government entity. EDB Investments, EDB and the Singapore government may be deemed to have shared voting and dispositive power over the shares owned beneficially and of record by Biomedical Sciences Investment Fund Pte Ltd and Singapore Bio-Innovations Pte Ltd. Jeremy Loh, one of the Issuer's directors, is a Vice President (Investments), San Francisco Center for EDB Investments Pte Ltd, Singapore. Dr. Loh disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
5. Reflects a 1-for-1.73 reverse stock split of the Issuer's outstanding shares effected on February 3, 2011.
6. Each share has no expiration date.
7. Reflects the automatic conversion of each share of Series C Preferred Stock and Series D Preferred Stock into one share of Common Stock to occur upon the closing of the Issuer's initial public offering. Each share has no expiration date.
8. Singapore Bio-Innovations Pte Ltd is the record holder of the securities reported on Line 4 of Table 2.

[Matthew McCardell](#) [02/10/2011](#)

[Matthew McCardell](#) [02/10/2011](#)

[Matthew McCardell](#) [02/10/2011](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Fluidigm Corporation (the Company) hereby constitutes and appoints the responsible attorneys and paralegals of Gibson, Dunn Crutcher LLP, and each of them, as the undersigned's true and lawful attorney-in-fact to:

(1) complete and execute Forms ID, 3,4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his or her discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and (2) do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorney-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorney-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms ID, 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorney-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 8th day of February, 2011.

Biomedical Sciences Investment Fund Pte Ltd
Signature: /s/ Chu Sivee Yeok
Title: Director

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Fluidigm Corporation (the Company) hereby constitutes and appoints the responsible attorneys and paralegals of Gibson, Dunn Crutcher LLP, and each of them, as the undersigned's true and lawful attorney-in-fact to:

(1) complete and execute Forms ID, 3,4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his or her discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and
(2) do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorney-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorney-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms ID, 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorney-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 8th day of February, 2011.

EDB Investments Pte Ltd.
Signature: /s/ Chu Sivee Yeok
Title: Director

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Fluidigm Corporation (the Company) hereby constitutes and appoints the responsible attorneys and paralegals of Gibson, Dunn Crutcher LLP, and each of them, as the undersigned's true and lawful attorney-in-fact to:

(1) complete and execute Forms ID, 3,4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his or her discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and
(2) do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorney-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorney-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms ID, 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorney-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 8th day of February, 2011.

Singapore Bio-Innovations Pte Ltd
Signature: /s/ Eugene Khoo Kay Jin
Title: Director